A Case of Diabetic Ketoacidosis Associated with Risperidone Treatment

Risperidon Tedavisi ile İlişkili Diyabetik Ketoasidoz Vakası

Abdullah Taşlıpinar, Mahmut Yazıcı, Levent Kebapçılı, Deniz Engin Gök, Mustafa Şahin, *Sinan Yetkin, Erol Bolu, Zeynel Beyhan, Mustafa Kutlu

Department of Internal Medicine, Division of Endocrinology and Metabolism, Gulhane Military Medical Faculty, Ankara, Turkey
*Department of Psychiatry, Gulhane Military Medical Faculty, Ankara, Turkey

Abstract
The association between schizophrenia and diabetes has been previously documented. Case reports have also demonstrated that initiation of atypical antipsychotic agents may induce or exacerbate diabetes mellitus. A 26-year-old man without a family history of diabetes mellitus presented with deep coma after 5 months of treatment with risperidone. He was diagnosed with diabetic ketoacidosis, was given insulin and saline infusion, and his antipsychotic agent was changed from risperidone to ziprasidone. Insulin therapy and oral agent was discontinued within two months of follow-up. The rapid onset of diabetes, and the disappearance of hyperglycemia after discontinuation of the drug suggested that risperidone had been a factor in his diabetic ketoacidosis. During three years of subsequent follow-up, testing revealed no evidence of elevated serum glucose levels or impaired glucose tolerance. In our opinion psychiatrists should routinely ask patients treated with antipsychotic agents such as risperidone for diabetic symptoms, weight loss, lethargy, polydipsia and/or polyuria, and monitor serum glucose levels. Although there is no consensus on the best way to switch from one antipsychotic drug to another, for those patients who develop diabetes during therapy with risperidone a change to ziprasidone treatment may maintain normal glucose levels. Turk Jem 2008; 12: 97-8

Keywords: Risperidone, diabetes mellitus, ziprasidone

Özvet

Anahtar kelimeler: Risperidon, diyabet, ziprasidon

Introduction
There is evidence to suggest that atypical antipsychotic medications can increase the risk of diabetes mellitus (1,2). Cases have ranged in severity from mild glucose intolerance to hyperosmolar coma or diabetic ketoacidosis, a rare but potentially fatal metabolic complication (2,3). In these reports, most cases of new-onset disturbances of glucose homeostasis improved after changing antipsychotic medication. However, there is no consensus on the best way to change from one antipsychotic drug to another. A successful
approach may be gradual discontinuation of the current antipsychotic drug and immediate initiation of the new treatment (4). According to recent reviews, the risk of diabetes is highest for clozapine and olanzapine, followed by quetiapine and risperidone, and lowest for those receiving ziprasidone treatment (2,5).

Given these limited data, a strong causal association is indicated between the use of risperidone and hyperglycemia. This may help to reinforce the concept that this agent may precipitate diabetic ketoacidosis. Ziprasidone treatment does not appear to contribute to these metabolic abnormalities.

Case Report

The patient was a 26-year-old male with a long-standing history of schizophrenia with poor medication adherence, resulting in frequent hospitalizations. After five months of treatment with risperidone (6 mg daily), he was noted to be confused and lethargic and was admitted to our emergency department. On admission, height was 177.0 cm and weight was 93 kg, BMI=31 kg/m²; pulse rate was 110 beats/min, and blood pressure was 95/75 mm Hg. Laboratory investigation revealed a random glucose of 338 mg/dL and a glycosylated hemoglobin of 11.2%. Homeostasis model assessment (HOMA) index was calculated 4.04. Biochemical evaluation suggested metabolic acidosis with ketonemia (pH: 7.23, sodium 127, chloride 92, 3+ by reagent strip testing). The patient was diagnosed with diabetic ketoacidosis. The patient was emergently admitted to the intensive care unit and treated with aggressive intravenous hydration and insulin infusion. On his return to the psychiatric inpatient unit, it was decided to discontinue risperidone treatment and switch to ziprasidone (80 mg daily) for management of schizophrenic symptoms. Autoantibodies to GAD65 or IA-2 were negative in our patient. Intravenous administration of insulin was replaced by intermittent subcutaneous administration; serum glucose was maintained in a normal range by dietary therapy alone (25 kcal/kg/day) within two months. In three years of subsequent follow-up, oral glucose tolerance tests were used to assess changes in glucose levels; neither impaired glucose tolerance nor high levels of fasting plasma glucose was observed. The patient's lipid profile and weight did not change during ziprasidone treatment.

Discussion

Schizophrenia is a risk factor for new-onset type 2 diabetes. The causative factors are partly explained by obesity, cigarette smoking, physical inactivity, and insulin resistance (6-8). There is also evidence to suggest that atypical antipsychotics can increase the risk of diabetes mellitus (1,2). Diabetic ketoacidosis is one of a spectrum of metabolic disorders that have been linked to the use of atypical antipsychotic agents (2,3).

The mechanism by which the atypical antipsychotics cause hyperglycemia remains unclear. The ability of various drugs in this class to cause hyperglycemia varies. Case reports of adverse effects on glucose and lipid metabolism (for example, type 2 diabetes mellitus and dyslipidemia) have more frequently and consistently been associated with clozapine and olanzapine treatment than with quetiapine or risperidone treatment (2,5).

In our case, rapid development of uncontrolled diabetes with metabolic acidosis, disappearance of hyperglycemia after discontinuation of risperidone, and lack of recurrence with ziprasidone treatment suggest that the development of diabetes in this patient was a risperidone-related effect. Case studies have shown a significantly greater risk of hyperglycemia with risperidone than with ziprasidone treatment.

We searched cases of risperidone-associated diabetes or hyperglycemia in the literature for information on the type of diabetes mellitus and dyslipidemia) have more frequently and consistently been associated with clozapine and olanzapine treatment than with quetiapine or risperidone treatment (2,5).

In our case, rapid development of uncontrolled diabetes with metabolic acidosis, disappearance of hyperglycemia after discontinuation of risperidone, and lack of recurrence with ziprasidone treatment suggest that the development of diabetes in this patient was a risperidone-related effect. Case studies have shown a significantly greater risk of hyperglycemia with risperidone than with ziprasidone treatment.

The mechanism by which the atypical antipsychotics cause diabetes mellitus and dyslipidemia) have more frequently and consistently been associated with clozapine and olanzapine treatment than with quetiapine or risperidone treatment (2,5).

In our case, rapid development of uncontrolled diabetes with metabolic acidosis, disappearance of hyperglycemia after discontinuation of risperidone, and lack of recurrence with ziprasidone treatment suggest that the development of diabetes in this patient was a risperidone-related effect. Case studies have shown a significantly greater risk of hyperglycemia with risperidone than with ziprasidone treatment.

The mechanism by which the atypical antipsychotics cause diabetes mellitus and dyslipidemia) have more frequently and consistently been associated with clozapine and olanzapine treatment than with quetiapine or risperidone treatment (2,5).

In our case, rapid development of uncontrolled diabetes with metabolic acidosis, disappearance of hyperglycemia after discontinuation of risperidone, and lack of recurrence with ziprasidone treatment suggest that the development of diabetes in this patient was a risperidone-related effect. Case studies have shown a significantly greater risk of hyperglycemia with risperidone than with ziprasidone treatment.

Given these limited data, a strong causal association is indicated between the use of risperidone and hyperglycemia. This may help to reinforce the concept that this agent may precipitate diabetic ketoacidosis. Ziprasidone treatment does not appear to contribute to these metabolic abnormalities.

References